Proteins and Peptides

28 June 2014

Lundbeck provides update on the development program for desmoteplase

27 June 2014

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

27 June 2014

Janssen Submits EU Marketing Application for VELCADE® (bortezomib) in Mantle Cell Lymphoma

27 June 2014

CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union

26 June 2014

Nora Therapeutics Announces Initiation of Phase 2 RESPONSE Research Study

25 June 2014

Flamel Technologies Announces Positive Preclinical Results For Its Once-a-Week Formulation of Exenatide

25 June 2014

Sobi files for EU approval of Xiapex for Peyronies disease

24 June 2014

Zealand provides an update on activities relating to danegaptide for the protection of cardiac tissue against reperfusion injuries

24 June 2014

OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder

24 June 2014

Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment

23 June 2014

Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results

22 June 2014

Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo

22 June 2014

New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk markers and fewer people progressing to prediabetes compared with placebo in adults with obesity

21 June 2014

Teijin Pharma to Develop Sheet-type Fibrin Sealant for Surgical Operations

19 June 2014

Apitope Progresses Graves’ Disease Treatment

18 June 2014

Hetero Launches Darbepoetin Alfa, a Much Needed Biosimilar Anemia Treatment in India

18 June 2014

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease

18 June 2014

Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

18 June 2014

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

16 June 2014

Phase 3a Data Showed Liraglutide 3 mg Demonstrated Significantly Greater Weight Loss Compared to Placebo in Adults With Obesity and Type 2 Diabetes

16 June 2014

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

16 June 2014

New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People with Type 2 Diabetes

16 June 2014

New Phase 3 Study Shows Efficacy and Safety of Victoza® (Liraglutide [rDNA origin] Injection) for the Treatment of Type 2 Diabetes in Adults with Moderate Renal Impairment

16 June 2014

Lilly’s Basal Insulin Peglispro Shows Novel Mechanism of Action

16 June 2014

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus

16 June 2014

Sanofi’s Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine

16 June 2014

Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)

16 June 2014

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

14 June 2014

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement

14 June 2014

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Mesothelin-Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Nectin-4-Targeted Immunotherapy Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

FcRn Inhibitors Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins